Gip - gastric inhibitory polypeptide Gene

Also Known as Gludins; RATGLUDINS

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 25040

Summary

Enables signaling receptor binding activity. Involved in several processes, including positive regulation of cell communication; positive regulation of glucose transmembrane transport; and triglyceride homeostasis. Located in cytoplasm; extracellular space; and neuronal cell body. Used to study type 2 diabetes mellitus. Biomarker of hyperinsulinism; hypothyroidism; obesity; and pancreas disease. Human ortholog(s) of this gene implicated in obesity and type 2 diabetes mellitus. Orthologous to human GIP (gastric inhibitory polypeptide). [provided by Alliance of Genome Resources, Apr 2022]

Gip Products (1)

mRNA Protein Name
NM_019630.3 NP_062604.1 gastric inhibitory polypeptide precursor

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables signaling receptor binding IMP
IMP: Inferred from mutant phenotype
8958204 RGD
Biological Process GO Annotation Evidence References Source
involved in digestive system development IEP
IEP: Inferred from expression pattern
8674860 RGD
involved in female pregnancy IEP
IEP: Inferred from expression pattern
7716131 RGD
involved in long-term synaptic potentiation IDA
IDA: Inferred from direct assay
18234983 RGD
involved in positive regulation of D-glucose transmembrane transport IMP
IMP: Inferred from mutant phenotype
8843773 RGD
involved in positive regulation of cAMP/PKA signal transduction IMP
IMP: Inferred from mutant phenotype
8958204 RGD
involved in positive regulation of insulin secretion IMP
IMP: Inferred from mutant phenotype
8958204 RGD
involved in positive regulation of synaptic transmission IDA
IDA: Inferred from direct assay
18234983 RGD
involved in response to acidic pH IMP
IMP: Inferred from mutant phenotype
34554 RGD
involved in response to amino acid IEP
IEP: Inferred from expression pattern
6376308 RGD
involved in response to axon injury IEP
IEP: Inferred from expression pattern
19170165 RGD
involved in response to carbohydrate IEP
IEP: Inferred from expression pattern
18685191 RGD
involved in response to glucose IEP
IEP: Inferred from expression pattern
8931636 RGD
involved in response to lipid IEP
IEP: Inferred from expression pattern
19520739 RGD
involved in response to nutrient levels IEP
IEP: Inferred from expression pattern
19056762 RGD
involved in response to organic cyclic compound IEP
IEP: Inferred from expression pattern
6753106 RGD
involved in response to peptide hormone IEP
IEP: Inferred from expression pattern
7937351 RGD
involved in response to selenium ion IEP
IEP: Inferred from expression pattern
11950233 RGD
involved in response to starvation IEP
IEP: Inferred from expression pattern
7599968 RGD
involved in response to xenobiotic stimulus IEP
IEP: Inferred from expression pattern
16402076 RGD
involved in triglyceride homeostasis IMP
IMP: Inferred from mutant phenotype
1816061 RGD
Cellular Component GO Annotation Evidence References Source
located in extracellular space IDA
IDA: Inferred from direct assay
19520739 RGD
located in neuronal cell body IDA
IDA: Inferred from direct assay
19170165 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

gastric inhibitory polypeptide

  • Glucose-dependent insulinotropic peptide

  • glucose-dependent insulinotropic polypeptide

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (6)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-13749 Sitagliptin Inhibitor 99.94% Yes
HY-13749A Sitagliptin phosphate Inhibitor 99.88% Yes
HY-13749B Sitagliptin phosphate monohydrate Inhibitor 99.83% Yes
HY-13749AR Sitagliptin phosphate (Standard) Inhibitor 99.82% Unkown
HY-13749E Sitagliptin hydrochloride Inhibitor / Unkown
HY-13749R Sitagliptin (Standard) Inhibitor / Unkown

Clinical Phase

Bioactive Molecules (6)
Cat. No. Product Name Effect
Purity Phase
HY-164535 Maridebart cafraglutide 99.24% Phase 3
HY-P11666 Brenipatide Agonist 99.29% Phase 3
HY-P11672 Poterepatide Agonist 99.78% Phase 3
HY-P10959 Macupatide Agonist 99.99% Phase 2
HY-P10591 Olatorepatide 99.35% Phase 2
HY-156073 LY3325656 Agonist / Phase 1

Pre-clinical Phase

Bioactive Molecules (61)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P0276 GIP, human Agonist 99.94% Unkown
HY-P10138 human GIP(3-30), amide Antagonist 99.76% Unkown
HY-P3247 [D-Ala2]-GIP (human) Agonist 99.95% Unkown
HY-P0276A GIP, human TFA Agonist 99.15% Unkown
HY-P10735 GIP (mouse) 98.79% Unkown
HY-P2542 GIP (3-42), human Antagonist 99.75% Unkown
HY-P10138A human GIP(3-30), amide TFA Antagonist 96.90% Unkown
HY-P2080B GIP (1-30) amide,human acetate Agonist 99.27% Unkown
HY-P1434 [Pro3]-GIP (mouse) Antagonist 98.84% Unkown
HY-P5390A GIP, rat TFA 99.81% Unkown
HY-P11285A LAGIPRA peptide TFA Agonist 99.86% Unkown
HY-P3579 Gastric Inhibitory Peptide, porcine 99.12% Unkown
HY-P10302A GLP-1R/GIPR agonist-1 (soduim) Agonist 98.24% Unkown
HY-P11321A IUB0271 hydrochloride Agonist 98.67% Unkown
HY-P3584A (Pro3) GIP, human TFA 99.89% Unkown
HY-P2541A GIP (1-30) amide, porcine TFA Agonist 99.14% Unkown
HY-P10959A Macupatide acetate Agonist 99.95% Unkown
HY-P10929 Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH 99.31% Unkown
HY-P11271A Ribupatide TFA Agonist 99.75% Unkown
HY-13749AS Sitagliptin-d4 phosphate Inhibitor 99.48% Unkown
HY-P3580A Acetyl Gastric Inhibitory Peptide (human) TFA 99.70% Unkown
HY-13749S1 Sitagliptin-d4 hydrochloride Inhibitor 99.36% Unkown
HY-153476A GIP/GLP-1 dual receptor agonist-1 sodium Agonist 98.33% Unkown
HY-P10302 GLP-1R/GIPR agonist-1 Agonist / Unkown
HY-P10965 Zovaglutide Agonist / Unkown
HY-P11271 Ribupatide Agonist 98.74% Unkown
HY-P2080C GIP (1-30)-Myr Agonist / Unkown
HY-P3255 DA-JC4 Agonist 99.27% Unkown
HY-P3584 (Pro3) GIP, human Agonist 99.79% Unkown
HY-103545 GIP (1-39) Agonist / Unkown
HY-120493 (rel)-AM-6226 Agonist / Unkown
HY-120493A AM-6226 Agonist / Unkown
HY-13749S2 Sitagliptin-d4 Inhibitor / Unkown
HY-153476 GIP/GLP-1 dual receptor agonist-1 Agonist 98.33% Unkown
HY-162513 DPP-4-IN-10 Inhibitor / Unkown
HY-171302 GLP-1R/GIPR agonist-2 Agonist / Unkown
HY-E70397A Dipeptidyl Peptidase IV, Porcine Kidney / Unkown
HY-P0165B Taspoglutide acetate Agonist / Unkown
HY-P0276F GIP, Cy5 labeled TFA / Unkown
HY-P10952 Astepatide Agonist / Unkown
HY-P10972 GIP (22-51) human / Unkown
HY-P11233 Acmopatide Agonist / Unkown
HY-P11270 Relsipatide Agonist / Unkown
HY-P11285 LAGIPRA peptide Agonist / Unkown
HY-P11321 IUB0271 Agonist / Unkown
HY-P11674 Zantrutide Agonist / Unkown
HY-P1433 [Pro3]-GIP (Rat) Agonist / Unkown
HY-P2080 GIP (1-30) amide,human Agonist / Unkown
HY-P2541 GIP (1-30) amide, porcine Agonist / Unkown
HY-P3577 [Tyr0] Gastric Inhibitory Peptide (23-42), human / Unkown
HY-P3578 Gastric Inhibitory Polypeptide (1-30), porcine Modulator / Unkown
HY-P3580 Acetyl Gastric Inhibitory Peptide (human) / Unkown
HY-P5390 GIP, rat / Unkown
HY-RS01726 C1QTNF1 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS05434 GIP Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS05535 GNAI2 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-13749S3 Sitagliptin-d6 Inhibitor / Unkown
HY-174832 DPP-4-IN-16 Inhibitor / Unkown
HY-184966 GIPR antagonist 4 Agonist / Unkown
HY-RS16530 Gip Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS22961 Gip Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Gip NCBI NCBI:2695